Literature DB >> 33420952

Reductions in liver cirrhosis hospitalizations during the COVID-19 pandemic.

Jianglei Li1,2, Deliang Liu1,2, Jin Yan1,2, Yuyong Tan3,4.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33420952      PMCID: PMC7796693          DOI: 10.1007/s12072-020-10127-w

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


× No keyword cloud information.

Introduction

The coronavirus disease-2019 (COVID-19) pandemic has changed the world and placed a huge strain on health care systems worldwide. Many hospitals have intentionally reduced non-emergency procedures and hospitalizations for some reasons. Some studies [1-4] have confirmed that the number of hospital admissions decreased significantly during this period. For hospitalized patients with liver cirrhosis, there is still no relevant research in China. This study aimed to explore the impact of the COVID-19 pandemic on the hospitalization of patients with liver cirrhosis (Table 1).
Table 1

Admissions of cirrhotic patients

Admissions of cirrhotic patients2016–20192020p value
Admission (range)351 (334–391)63
Gender, n (%)
Male258 (73.5%)50 (79.4%)0.293
Female93 (26.5%)13 (20.6%)
Age—years, average (range)52.7 (8–90)49.6 (18–79)0.0250
Etiology of cirrhosis, n (%)
 Viral hepatitis234 (66.7%)47 (74.6%)0.388
 Alcohol18 (5.1%)1 (1.6%)
 Autoimmune hepatitis7 (2.0%)1 (1.6%)
 Hepatolenticular degeneration6 (1.7%)1 (1.6%)
 Two or more causes32 (9.1%)7 (11.1%)
 Unknown reason32 (9.1%)6 (9.5%)
 Others22 (6.3%)
Admitted through the emergency department (%)28 (8.0%)22 (34.9%)< 0.05
Admitted due to gastrointestinal bleeding (%)61 (17.4%)26 (41.3%)< 0.05
Complicated hepatic encephalopathy (%)16 (4.6%)1 (1.6%)0.278
Length-of-stay (range)15.3 (1–180)14.0 (1–44)0.2263
Child-Turcotte–Pugh score (range)7.8 (5–14)7.7 (5–12)0.3705
Child-Turcotte–Pugh grade
 A117 (33.3%)20 (31.7%)0.947
 B151 (43.0%)27 (42.9%)
 C83 (23.7%)16 (25.4%)
Admissions of cirrhotic patients

Methods

We searched the hospitalizations records for liver cirrhosis in a tertiary hospital (The Second Xiangya Hospital). We examined the records of patients with liver cirrhosis who were hospitalized from January 21st, 2020 to March 31st, 2020 (from the first reported patient to the time of downgrading to third-level public health emergency in Hunan Province) and collected their clinical characteristics. We also collected the clinical characteristics of the patients with liver cirrhosis who were hospitalized from the same period in 2016–2019 for comparison.

Results

A total of 63 patients met the inclusion criteria in 2020, among whom 50 (79.4%) were male, and the average age was 49.6 years. In 2016–2019, 351 (ranging from 334 to 391) patients met the inclusion criteria, among whom 258 (73.5%) were male, and the average age was 52.7 years. The number of admissions decreased greatly during the COVID-19 pandemic. Viral hepatitis was the main cause of liver cirrhosis (74.6% in 2020 and 66.7% in 2016–2019). Twenty two (34.9%) of 63 patients in 2020, and 28 (8.0%) of 351 in 2016–2019 (p < 0.05) were admitted through the emergency department. Twenty six (41.3%) of 63 patients and 61 (17.4%) of 351 patients were hospitalized for gastrointestinal bleeding in 2020 and 2016–2019 respectively, p < 0.05. Only 1 patient (1.6%) had hepatic encephalopathy in 2020, while 16 (4.6%) of 351 were recorded in 2016–2019, p = 0.278. At admission, the severity of liver disease as assessed by CTP scores and grades did not differ between 2020 and 2016–2019 (CTP score: 7.7 in 2020 vs. 7.8 in 2016–2019, p = 0.3705; CTP grade: A:B:C 20:27:16 in 2020 vs. 117:151:83 in 2016–2019, p = 0.947). The average length-of-stay (LOS) was 14.0 days in 2020 and 15.3 days in 2016–2019, p = 0.2263.

Discussion

Recent studies [3, 5] showed different results. One study showed that the number of hospital admissions decreased significantly while another showed the opposite result. Our study showed that the hospitalizations decreased greatly compared to the previous years, while the severity and LOS did not vary. However, we found that the proportion of patients admitted due to gastrointestinal bleeding and through the emergency department increased significantly, which may be because hematemesis or black stools are fatal and more likely to alarm people, and some patients did not come to the hospital until their conditions worsened. The number of beds did decrease to about 50% due to lack of staff (they were assigned to help control the COVID-19 crisis). However, once the patient asked for hospitalization, he/she would be admitted as there still had empty beds during the pandemic. Thus we think the dramatically decreased numbers may be mainly due to the decreased number of consultation of these patients, which may be because they were afraid of going to hospital. In the current situation of the COVID-19 pandemic, further studies will be needed to investigate the decline in hospitalization rates for liver cirrhosis when national and social isolation measures are adopted. From a public health perspective, more studies are needed to determine whether this is related to adverse long-term results.
  5 in total

1.  Trends in cirrhosis hospitalizations during the COVID-19 pandemic.

Authors:  R Gaspar; R Liberal; Catarina Castelo Branco; G Macedo
Journal:  Dig Liver Dis       Date:  2020-07-15       Impact factor: 4.088

2.  Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic.

Authors:  Michael E Hall; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Lampros Papadimitriou; Robert C Long; Gabriel A Hernandez; Charles K Moore; Brandon W Lennep; Michael R McMullan; Javed Butler
Journal:  J Card Fail       Date:  2020-05-13       Impact factor: 5.712

3.  Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy.

Authors:  Ovidio De Filippo; Fabrizio D'Ascenzo; Filippo Angelini; Pier Paolo Bocchino; Federico Conrotto; Andrea Saglietto; Gioel Gabrio Secco; Gianluca Campo; Guglielmo Gallone; Roberto Verardi; Luca Gaido; Mario Iannaccone; Marcello Galvani; Fabrizio Ugo; Umberto Barbero; Vincenzo Infantino; Luca Olivotti; Marco Mennuni; Sebastiano Gili; Fabio Infusino; Matteo Vercellino; Ottavio Zucchetti; Gianni Casella; Massimo Giammaria; Giacomo Boccuzzi; Paolo Tolomeo; Baldassarre Doronzo; Gaetano Senatore; Walter Grosso Marra; Andrea Rognoni; Daniela Trabattoni; Luca Franchin; Andrea Borin; Francesco Bruno; Alessandro Galluzzo; Alfonso Gambino; Annamaria Nicolino; Alessandra Truffa Giachet; Gennaro Sardella; Francesco Fedele; Silvia Monticone; Antonio Montefusco; Pierluigi Omedè; Mauro Pennone; Giuseppe Patti; Massimo Mancone; Gaetano M De Ferrari
Journal:  N Engl J Med       Date:  2020-04-28       Impact factor: 91.245

4.  Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China.

Authors:  Chor-Cheung Frankie Tam; Kent-Shek Cheung; Simon Lam; Anthony Wong; Arthur Yung; Michael Sze; Yui-Ming Lam; Carmen Chan; Tat-Chi Tsang; Matthew Tsui; Hung-Fat Tse; Chung-Wah Siu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-03-17

5.  Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study.

Authors:  Nadim Mahmud; Rebecca A Hubbard; David E Kaplan; Marina Serper
Journal:  Gastroenterology       Date:  2020-05-06       Impact factor: 33.883

  5 in total
  1 in total

1.  Effect of COVID-19 on presentations of decompensated liver disease in Scotland.

Authors:  Thomas Manship; Paul N Brennan; Iona Campbell; Stewart Campbell; Thomas Clouston; John F Dillon; Ewan Forrest; Andrew Fraser; Tee Lin Goh; Michael Johnston; Muhammad I Khan; Victoria Livie; Iain A Murray; Jayne Saunders; Debbie Troland; Ken J Simpson
Journal:  BMJ Open Gastroenterol       Date:  2022-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.